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hAG-2 and hAG-3 are recently discovered human homologues of the secreted Xenopus laevis proteins XAG-1/2 (AGR-1/2) that are
expressed in the cement gland, an ectodermal organ in the head associated with anteroposterior fate determination during early
development. Although the roles of hAG-2 and hAG-3 in mammalian cells are unknown, both proteins share a high degree of protein
sequence homology and lie adjacent to one another on chromosome 7p21. hAG-2 mRNA expression has previously been
demonstrated in oestrogen receptor (ER)-positive cell lines. In this study, we have used real-time quantitative RT – PCR analysis and
immunohistochemistry on tissue microarrays to demonstrate concordant expression of hAG-2 and hAG-3 mRNA and protein in
breast tumour tissues. Tumour expression of both genes correlated with OR (hAG2, P¼0.0002; hAG-3, P¼0.0012), and inversely
correlated with epidermal growth factor receptor (EGFR) (P¼0.003). Yeast two-hybrid cloning identified metastasis-associated GPI-
anchored C4.4a protein and extracellular alpha-dystroglycan (DAG-1) as binding partners for both hAG-2 and hAG-3, which if
replicated in clinical oncology would demonstrate a potential role in tumour metastasis through the regulation of receptor adhesion
and functioning. hAG-2 and hAG-3 may therefore serve as useful molecular markers and/or potential therapeutic targets for
hormone-responsive breast tumours.
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Breast cancer is the most frequently diagnosed cancer in women
and accounts for 30% of all cancers diagnosed in the United States
(Greenlee et al, 2000). The implementation of screening pro-
grammes for the early detection of breast cancer, and the advent of
anticancer treatments, such as chemotherapy, radiotherapy and
antioestrogen therapies, to augment surgical resection have
improved the survival of breast cancer patients. However, even
breast tumours with good prognoses such as ER positive ductal
carcinoma in situ (DCIS) become refractory to such treatments as
the cancer cells develop resistance to chemotherapy drugs or lose
their hormone sensitivity, leading to recurrent or metastatic
disease that is often incurable. Thus, further characterisation of the
molecular pathology of breast cancer (including hormone-
responsive tumours) remains a key requirement in the develop-
ment of better treatments.
In a previous proteomic analysis of purified membrane
preparations from multiple human breast tumour-derived cell
lines (Adam et al, in press) we identified a unique protein
BCMP11. BCMP11 was homologous to hAG-2 (Genbank entry
NM006408.2), an uncharacterised human protein encoded by a
cDNA cloned from the MCF-7 breast cancer cell line (Thompson
and Weigel, 1998) and localised to chromosomal band 7p21.3
(Petek et al, 2000). In view of the high degree of sequence identity
(71%) between the two proteins, and the fact that they lie adjacent
to one another at chromosomal position 7p21, we named BCMP11
as hAG-3 (Genbank entry AY069977). The functions of both hAG-2
and hAG-3 are unknown; however, they are related to the Xenopus
laevis proteins XAG-1/AGR-1 and XAG-2/AGR-2. XAG-1 and
XAG-2 are expressed in ectodermal cells during the development
of the cement gland, a mucus-secreting organ in the head that is
involved in the attachment of the frog embryo to a solid support
(Sive et al, 1989). Indeed, the finding that XAG-2 is involved in the
regulation of dorsoanterior ectodermal cell fate during cement
gland differentiation (Aberger et al, 1998) suggests its potential
role as a differentiation factor. hAG-2 and hAG-3 each have a
predicted N-terminal cleavable secretory signal sequence (http://
psort.nibb.ac.jp) and we previously demonstrated that hAG-3 was
localised to endosomes in the T47D breast cancer cell line, further
evidence that it is a secreted protein (Adam et al, in Press). hAG-2
was identified in a number of ER-positive breast cancer cell lines
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s(Thompson and Weigel, 1998) and we previously demonstrated
expression of hAG-3 immunohistochemically in breast cancer
tissues (Adam et al, in Press).
Here we demonstrate using immunohistochemical and real-time
quantitative RT–PCR analysis that hAG-2 and hAG-3 mRNA and
protein exhibit a remarkably similar expression pattern in breast
cancer tissues that strongly correlates with OR status and inversely
with EGFR status. Furthermore, yeast two-hybrid cloning identi-
fied metastasis-associated GPI-anchored C4.4a protein and extra-
cellular alpha-dystoglycan (DAG-1) as binding partners for both
hAG-2 and hAG-3. These observations are intriguing since if they
can be verified in clinical tumours they would suggest a potential
role in breast tumour establishment and metastasis through
secretion, cell and extracellular matrix (ECM) adhesion, and
regulation of receptor function.
MATERIALS AND METHODS
Real-time quantitative RT–PCR
Real-time quantitative RT–PCR analysis of gene expression (Heid
et al, 1996; Morrison et al, 1998) was carried out on first-strand
cDNA derived from RNA isolated from samples of breast tumour
tissues (provided by Prof AL Harris, University of Oxford, UK). All
clinical samples were obtained with informed patient’s consent and
ethical approval. Each PCR reaction contained 10ng first-strand
cDNA (prepared from each mRNA sample using Superscriptt
reverse transcriptase, Life Technologies, Carlsbad, CA, USA),
SYBR green sequence detection reagents (Applied Biosystems,
Foster City, CA, USA), and sense and antisense primers. All primer
pairs traverse at least one intron and test products have been
sequenced to confirm specificity before use in these assays. PCR
products from all samples were analysed on agarose gels and
positives shown to contain a single PCR product of the size
predicted from cDNA. No fragments of the size predicted from
genomic DNA were detected in any samples demonstrating the
complete absence of genomic DNA contamination. All reactions
were run twice and any samples showing a 410% variation in
copy number excluded from analysis. The hAG-2 primers used
were: F, agataccacagtcaaacctg (exon2): R, gcactcatccaagtgatgaa
(exon4, inter-exon distance¼652bps) and hAG-3 primers were: F,
ctggaggattgtcaatactc (exon3); R, gcataaggtttagcatgat(exon4, inter-
exon distance¼678bps). The C4.4a primers used were: F,
aagaatgaccgcggcctggatc (exon3); R, gacatgatcgctggcgttgtag (exon4,
inter-exon distance¼643bps). The PCR conditions used for all
sets of primers were 1 cycle at 951C for 10min, and 40 cycles at
951C for 15s, 57.51C for 1min. Reaction products were assayed on
an ABI Prism 7700 sequence detection system (Applied Biosys-
tems, Foster City, CA, USA) and the accumulation of PCR product
was measured in real time as the increase in SYBR green
fluorescence. Data were analysed using the Sequence Detector
program v1.6.3 (Applied Biosystems, Foster City, CA, USA).
Standard curves relating initial template copy number to
fluorescence and amplification cycle were generated using the
amplified PCR product as a template, and were used to calculate
mRNA copy number in each sample. Data were expressed as copy
number per nanogram cDNA.
Immunohistochemistry
The hAG-2 polyclonal antibody was raised in rabbits immunised
with two specific peptides (Abcam Ltd, Cambridge, UK). Peptide
sequences were chosen for synthesis based on plots of hydro-
phobicity, antigenicity, surface probability, and minimal homology
to other known protein family members. Peptides were synthesised
using Fmoc chemistry with a cysteine residue added to the end of
each to enable specific thiol-reactive coupling of Keyhole Limpet
Haemocyanin prior to immunisation. The hAG-2 peptides used
were VKPGAKKDTKDSRPK and LVYETTDKHLSPDGQ. The
generation of the hAG-3 polyclonal antibodies has been described
previously (Adam et al, in press). The ER monoclonal antibody
(Dako Ltd., Glostrup, Denmark) is specific for the N-terminal
region of ERa.
Immunohistochemical analysis was carried out on formalin-
fixed paraffin-embedded tissue microarrays containing 1mm
sections of breast carcinoma tissues from 60 donors (obtained
from Clinomics Laboratories Inc., Pittsfield, MA, USA). Slides were
deparafinised by two 5min washes in xylene, then rehydrated
through successive graded ethanol solutions and washed
for 5min in PBS. Antigen retrieval was achieved by immersing
the slides in 0.01 M citrate buffer (pH 6) and microwaving for
10min at full power (950W) and then treating the tissue with
pepsin (1mgml
 1) for 1.5min at room temperature at
pH 2. Endogenous hydrogen peroxidase activity was quenched
by treating the slides in 3% hydrogen peroxidase/PBS for
10min followed by two washes in PBS. The tissue was blocked in
10% donkey serum/PBS for 1h before addition of 2mgml
 1
primary polyclonal antibody (in 2.5% donkey serum). Following
three washes in PBS, the tissue sections were incubated with
biotin-conjugated secondary antibodies (Biotin-SP-conjugated
AffiniPure Donkey anti-rabbit, Jackson ImmunoResearch,
West Grove, PA, USA) diluted at 1:200 (2.5mgml
 1 in 2.5%
donkey serum/PBS) for 1h. Slides were washed three times
in PBS and the tissue incubated with streptavidin–HRP
(Jackson ImmunoResearch, West Grove, PA, USA) diluted 1:100
(5mgml
 1 in 2.5% donkey serum/PBS), followed by three 5-min
washes in PBS. Antibody signal was detected using DAB substrate
solution (DAKO Ltd., Glostrup, Denmark) according to the
manufacturer’s instructions. Sections were screened for the
presence of epithelial cells (Moll et al, 1982) using an anti-
cytokeratin antibody (DAKO Ltd., Glostrup, Denmark) according
to the manufacturer’s instructions. Those sections without
epithelial cells were not used.
Yeast two-hybrid cloning analysis
Baits were PCR amplified (Pfu, Stratagene, La Jolla, CA, USA) and
then cloned in the pB6 plasmid derived from the original pAS2DD
(Fromont-Racine et al, 1997). PCR fragments were subcloned
using classical enzymatic methods in a 96-well-plate format. All
bait constructs were fully sequenced before transformation into
yeast. The bait fragment used from hAG-2 was the predicted
mature protein (amino acids 21–175 of Accession NP_006399) and
did not contain the predicted cleaved signal sequence. An identical
strategy was used for hAG-3 using the predicted mature protein
(amino acids 24–166 of Accession AAL55402). Random and oligo
dT-primed cDNA libraries from human placenta poly(A
+) RNA
and separately from poly(A
+) RNA pooled from T47D, MCF7, MB-
MDA-468, and BT20 breast cancer-derived cell lines were
constructed into the pP6 plasmid derived from the original pACT2
plasmid (Rain et al, 2001) and transformed in Escherichia coli
(DH10B; Invitrogen, Carlsbad, CA, USA). The complexity of the
primary libraries was over 50 million clones. Sequence analysis
was performed on 300 randomly chosen clones to establish the
general characteristics of each library. The libraries were then
transformed into yeast and 10 million independent yeast colonies
were collected, pooled, and stored at  801C as equivalent aliquot
fractions of the same library.
The mating protocol has been described elsewhere (Fromont-
Racine et al, 1997). Briefly, the screening conditions were adapted
for each bait (test screen) before performing the full-size screen-
ing. The selectivity of the HIS3 reporter gene was modulated with
3-aminotriazole in order to obtain a maximum of 384 histidine-
positive clones. For all the selected clones, LacZ activity was
measured in a semiquantitative X-Gal overlay assay. The interact-
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analysed on an agarose gel, and sequenced at their 50 and 30
junctions on a PE3700 Sequencer. The resulting sequences were
then used to identify the corresponding gene in the GenBank
database (NCBI).
RESULTS
hAG-3 and hAG-2 share a high degree of sequence
homology and lie adjacent to one another at chromosomal
position 7p21
Figure 1A shows the protein sequence alignment of hAG-3 with
hAG-2. Overall, both proteins show 71% similarity (Jotun-Hein
method, 64% identity by BLASTP) with the majority of differences
being in the hydrophobic leader signal sequences. A BLAST
(Altschul et al, 1990) search of the ENSEMBL genomic database
(http://www.ensembl.org) with the hAG-3 coding sequence loca-
lised the gene to chromosome 7p21 (Figure 1B). The hAG-3
sequence is not linked to hAG-1, which lies on chromosome 1, but
is in the same genomic segment as hAG-2 (Petek et al, 2000),
transcribed from the same DNA strand and separated by
approximately 60kb of genomic DNA. Both hAG-2 and hAG-3
genes comprise seven coding exons with similar exon/intron
boundaries, which together with the high similarity and close
genomic locality suggest that they arose from a gene duplication
event.
Coexpression of hAG-2 and hAG-3 mRNA and protein in
ER-positive breast cancer tissues
Immunohistochemical analyses demonstrated that hAG-2, hAG-3,
and ER protein expression was detected in 48 (83%), 43 (74%), and
34 (59%), respectively, of 58 breast cancer sections. hAG-2 and
hAG-3 immunostaining was restricted to the cancerous epithelial
cells of the tumour tissue and was predominantly cytoplasmic
(Figure 2). Coexpression of hAG-2 and hAG-3 in the breast tumour
tissues was highly significant (Po0.0001). Expression of both
hAG-2 and hAG-3 also strongly correlated with OR expression
(hAG-2, P¼0.0002; hAG-3, P¼0.001), examples of breast tumour
sections showing immunostaining for all three proteins are shown
in Figure 2. Nevertheless, there were a number of ER-negative
breast cancers that expressed both hAG-2 and hAG-3.
For a more quantitative assessment of hAG-2 and hAG-3 levels
in breast tumour tissues and their association with several
biological parameters, we performed real-time quantitative RT–
PCR on 46 cDNA samples derived from breast tumour tissues. In
all, 23 of these tissues were derived from patients with lymph node
metastasis, the remaining 23 showed no lymph node metastasis.
The results of these analyses are shown in (Table 1). Both hAG-2
and hAG-3 showed a correlation with ER expression and a
negative correlation with EGFR expression (Table 1). Expression of
hAG-3, but not hAG-2, was associated with tumour grades I/II and
patients agedX50 years (Table 1). Moreover, there was no
significant association of either hAG-2 or hAG-3 expression in
the primary tumours with the presence of lymph node metastasis
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V    F     A    E    N    K    E    I    Q    K    L    A    E   Q    −      90 hag-2
V    F     A    Q   N    E    E    I     Q   E    M   A   Q     N   K    F     I    M     L    N    L   M   H    E    T    T     D   K   N    L  80 hag-3
S    P     D    G   Q   Y     V    P   R    I     M   F    V    D   P    S   L    T     V    R    A    D   I     T    G    R   Y    S   N    R 
S    P     D    G   Q   Y     V    P   R    I     M   F    V    D   P    S   L    T     V    R    A    D   I     A    G    R   Y    S   N    R 
119 hag-2
110 hag-3
L    Y     A    Y    E    P    A    D   T    A    L    L     L    D   N   M    K    K    A    L   K    L    L     K    T    E   L     149 hag-2
L    Y     T    Y     E   P    R    D   L    P    L     L    I     E    N   M   K    K     A    L  R    L    I      Q    S    E   L     140 hag-3
A
B 7p21.1
DNA (contigs) AC073333 AC098592
hAG-2
exons
hAG-3
16.476 Mb 16.544 Mb 16.564 Mb 16.450 Mb
Transcription
E    A     L    Y    K    S    K   T    S    N    K    P    L   M    I     I    H    H     L    D    E   C    P   H    S    Q   A    L    K   K
E    G     L    F    Y    A    Q   K   S    K    K    P    L   M    V    I    H    H     L    E    D   C    Q   Y    S    Q   A    L    K   K
M    E    K    I      P    V    S   A   F    −     L    L    L   V    A     L    S    Y     T    L    A   R    D   T    T    V   K    P    G   A
M    M     L    H    S    A    L   G   L    C    L    L    L   V    T    V    S    −     −     −    −    −    −    S    N    L   A    I     A     I
K    K    D    T     K    D    S   R   P   K    L    P    Q   T    L    S    R     G    W   G    D   Q    L   I     W    T   Q    T    Y   E
K    K     E    K    R     −   −    −    −    −   P    P    Q   T    L    S    R     G    W   G    D    D   I    T    W    V   Q    T    Y   E
F    V     L    L    N    L   V    Y    E    T    T     D   K   H    L
Figure 1 hAG-2 and hAG-3 show close homology at the protein level and are adjacent to each other at chromosome position 7p21. (A) Protein
sequence alignment of hAG-2 and hAG-3 (DNAStar MegAlign program–Jotun Hein alignment). The boxed regions on the hAG-3 sequence indicate exact
amino-acid matches of hAG-3 with hAG-2. (B) Diagram illustrating the genomic locations, transcriptional orientation, and exon structures of hAG-2 and
hAG-3 on chromosome 7p21.
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Figure 2 Immunohistochemical analysis of hAG-2, hAG-3, and ER protein in three separate breast ductal carcinoma donor tissue sections. The boxed
region in panels A, D,a n dG is magnified in panels J, K,a n dL, demonstrating cytoplasmic staining of hAG-2 (J) and hAG-3 (K) and nuclear staining of ER (L).
Table 1 Expression of hAG-3 and hAG-2 mRNA in 46 breast cancer samples
Gene Biological marker mRNA copy number median (range) Statistical significance
hAG-2 ER+ 13000 (2900–160000) P=0.01
ER  4500 (130–78000)
hAG-3 ER+ 5774 (88–30573) P=0.004
ER  183 (5–16961)
hAG-2 AgeX50years 11000 (130–160000) P=0.75
Ageo50years 8900 (600–130000)
hAG-3 AgeX50years 3738 (12–30573) P=0.05
Ageo50years 903 (5–6608)
hAG-2 EGFR  16000 (130–160000) P=0.009
EGFR+ 5650 (290–17000)
hAG-3 EGFR  5774 (63–30573) P=0.003
EGFR+ 233 (5–13216)
hAG-2 Tumour Grade I, II 12500 (150–160000) P=0.09
Tumour Grade III 4950 (130–130000)
hAG-3 Tumour Grade I, II 6295 (282–30573) P=0.006
Tumour Grade III 183 (5–16961)
hAG-2 and hAG-3 expression in 46 clinical breast cancer samples was quantified by real time RT-PCR. mRNA copy
number per ng cDNA was correlated with ER status (+, positive:  negative), age (less than 50 years of age versus 50 years
of age and over), EGFR status, and tumour grade (grades I and II vs grade III). Statistical significance was calculated using the
Mann Whitney U-test.
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positive primary breast cancers, OR expression is not associated
with node metastasis either.
In contrast to the breast tumour data, hAG-2 and hAG-3 were
not coexpressed in another hormone-responsive tumour type,
prostate cancer. Of 42 prostate cancer sections examined by
immunohistochemistry, 34 (81%) were immunoreactive for hAG-2
and only 7 (17%) immunoreactive for hAG-3. Examples of hAG-2
and hAG-3 immunostaining in the same donor prostate tumour
sections are demonstrated in Figure 3.
Both hAG-2 and hAG-3 proteins interact with metastasis-
associated C4.4a protein and alpha-dystroglycan (DAG-1)
The similarities between hAG-2 and hAG-3 and their significance
to breast cancer are further characterised by the interacting
proteins identified for hAG-2 and hAG-3 in a yeast two-hybrid
screen. We have already shown that hAG-3 interacts with the
human homologue of a rat GPI-anchored protein C4.4a (GenBank:
NM_014400) (Adam et al, in Press). Analysis of hAG-2 and hAG-3
bait proteins (with their signal sequences deleted) in the same
yeast two-hybrid system (Rain et al, 2001) using the same
placenta-derived prey library as well as a prey library derived
from a pool of four breast cancer cell lines (T47D, MCF7, BT20,
MDMBA468) identified C4.4a and dystroglycan (DAG1, GenBank
Accession XP_018223) as the only significant interacting partners
for both proteins. The significance of these interactions from
screening two prey libraries is defined by: (1) neither DAG-1 nor
C4.4a have been identified as binding partners in screens of more
than 250 other proteins in this yeast two-hybrid system (Daviet L,
unpublished observation), (2) both DAG-1 and C4.4a are identified
as binding partners for hAG-2 and hAG-3 from the placenta and
breast cancer prey libraries, (3) multiple clones for both DAG-1
(43) and C4.4a (8) with different but overlapping interaction
domains were observed for both hAG-2 and hAG-3 allowing
minimum binding domains to be defined for DAG-1 and C4.4a,
and (4) these minimum binding domains (Figure 4A) were
restricted to extracellular portions of DAG-1 (alpha dystroglycan
chain) and C4.4a consistent with the predicted secreted nature of
the hAG proteins.
Real-time quantitative RT–PCR analysis demonstrated that
C4.4a mRNA expression is elevated in seven clinical breast
tumours compared with the matched adjacent normal breast
tissue. In addition, C4.4a is also highly expressed in the four
human breast cancer-derived cell lines used for the construction of
the yeast two-hybrid library (Figure 4B). Clearly, further analyses
such as coimmunoprecipitation are required to confirm that these
interactions occur in clinical cancers but the consistency of the
yeast 2-hybrid data, the expression profile of C4.4a and the
previously reported links of DAG-1 and C4.4a to cancer make
these interactions intriguing enough to warrant further investiga-
tion.
DISCUSSION
We have characterised the expression profile and protein binding
partners of the two homologous, functionally uncharacterised
proteins, hAG-2 and hAG-3. Both genes lie adjacent to one another
at chromosomal position 7p21, are 71% identical and are
concordantly expressed in OR-positive breast tumour tissues.
Both hAG-2 and hAG-3 have also been shown to interact with the
same two proteins, C4.4a and alpha dystroglycan, in yeast two-
hybrid cloning assays using two different libraries.
The coexpression of hAG-2 and hAG-3 with oestrogen receptor
is intriguing. Indeed a search of the first 20kb of both the hAG-2
and hAG-3 promoters has identified four and 12 putative
oestrogen response elements, respectively (using an consensus
sequence of GGTCAnnnTGACC) (Schenker M, unpublished
observations). Despite the striking correlation of hAG-2 and
hAG-3 with OR, over half of the OR-negative breast tumours
examined immunohistochemically expressed hAG-2 and hAG-3,
suggesting a more penetrant role for both proteins in breast cancer
aetiology than is defined by OR alone. This suggests that both
hAG-2 and hAG-3 genes may be transcriptionally regulated by
factors in addition to OR. Indeed, the complete lack of correlation
between hAG-2 and hAG-3 expression in another hormone-
responsive cancer, namely prostate cancer, clearly indicates
differences in the transcriptional regulation of both genes.
The finding that hAG-2 and hAG-3, two unique secreted
proteins whose expression is elevated in OR-responsive breast
tumours, interact with the same two known extracellular proteins
in vitro, C4.4a and dystroglycan, could indicate a role for the hAG
proteins in the development and/or progression of breast cancer
hAG-2  
hAG-3
Section 1 
(5a)
Section 3 
(5e)
A B C
D E F
Section 1 Section 2 Section 3
Prostate adenocarcinoma tissues
Figure 3 hAG-2, but not hAG-3, protein is expressed in malignant prostate epithelial cells. Immunohistochemical analysis of hAG-2 and hAG-3 in three
prostate adenocarcinoma donor tissue sections.
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Xenopus embryos. Apart from its reported association with
metastasis (Rosel et al, 1998), C4.4a gene expression has recently
been shown to be elevated in urothelial cells exposed to matrigel in
vitro, a model designed to discover proteins involved in cell–cell
and cell–matrix interactions (Smith et al, 2001). Thus, the
observed yeast 2-hybrid interactions of both hAG proteins with
C4.4a could associate these secreted proteins with a GPI-anchored
receptor protein involved in hormone responsiveness, cell adhe-
sion, migration, and metastasis. As such, the hAG/C4.4a inter-
action may represent a viable target for oestrogen-responsive breast
cancer intervention. Moreover, our finding that C4.4a mRNA
expression is upregulated in breast cancer tissues compared with
adjacent normal tissues, and significantly expressed in a number of
breast cancer cell lines, further supports a clinically important role
for the association of the hAG proteins with C4.4a.
The minimum binding domain of dystroglycan (DAG-1) for
both hAG-2 and hAG-3 is shown in Figure 4A. This sequence
corresponds to the extracellular alpha dystroglycan chain of DAG-
1. The complete DAG-1 protein compromises two subunits, 43kDa
transmembrane and 156kDa extracellular, derived from the same
mRNA, and provides a link between the sarcolemma and
extracellular matrix through the binding of laminin (Ibraghimov-
Beskrovnaya et al, 1992). This provides further evidence that hAG-
2 and hAG-3 are secreted proteins and associated with the ECM.
Furthermore, DAG-1 interacts with and regulates caveolin-3
distribution which in turn affects alpha-integrin 7 receptor
expression (Sotgia et al, 2000; Cote et al, 2002) so that the hAG/
DAG-1 interaction could be affecting a further receptor pathway.
Alpha dystroglycan is almost undetectable in cancer cell lines by
Western blotting (Losasso et al, 2000), and this is reflected by the
low number of clones (2) obtained from the human breast cancer
cell line prey library compared with the placenta library (40). The
hAG/DAG-1 interaction could therefore have more of a paracrine
function than the hAG/C4.4a interaction, and thus be involved in
cell–cell interactions between cancer and noncancer cells and the
intervening extracellular matrix.
In summary, two of the three known members of the hAG family
of proteins show clear relevance to breast cancer that is
strengthened by their roles in Xenopus development, a significant
association with ER, and putative protein-binding partners that are
not only linked with cancer progression but provide opportunities
for those interactions to be targeted in the development of cancer
therapies.
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